Levofloxacin-based and clarithromycin-based triple therapies as first-line and second-line treatments for Helicobacter pylori infection: a randomised comparative trial with crossover design-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Levofloxacin-based and clarithromycin-based triple therapies as first-line and second-line treatments for Helicobacter pylori infection: a randomised comparative trial with crossover design

Published:2010-04-28 Issue:5 Volume:59 Page:572-578
ISSN:0017-5749
Container-title:Gut
language:en
Short-container-title:Gut

Author:

Liou J. M.,Lin J. T.,Chang C. Y.,Chen M. J.,Cheng T. Y.,Lee Y. C.,Chen C. C.,Sheng W. H.,Wang H. P.,Wu M. S.

Publisher

BMJ

Subject

Gastroenterology

Cited by 104 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Addressing Challenges in Standardizing Helicobacter pylori Treatment Protocols: Importance and Review;Cureus;2024-04-30

2. Role of AlgC and GalU in the Intrinsic Antibiotic Resistance of Helicobacter pylori;Infection and Drug Resistance;2023-03

3. Comparison of 10 and 14 days of antofloxacin-based versus 14 days of clarithromycin-based bismuth quadruple therapy for Helicobacter pylori eradication: A randomized trial;Clinics and Research in Hepatology and Gastroenterology;2023-01

4. Treatment of refractory Helicobacter pylori infection: A new challenge for clinicians;Frontiers in Microbiology;2022-10-18

5. Levofloxacin versus clarithromycin for Helicobacter pylori eradication: are 14 day regimens better than 10 day regimens?;Gut Pathogens;2022-06-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP